SCHEMBL10036305

SCHEMBL10036305

Cc1cc(Nc2ccc(Sc3ccncc3)cc2)nc(N)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 3/20 1.00
RAB9A P51151 3/20 0.61
CYP1A2 P05177 2/20 0.61
NPC1 O15118 2/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C19 P33261 1/20 0.61
CYP2D6 P10635 1/20 0.60
DNMT1 P26358 2/20 0.53
DNMT3L Q9UJW3 2/20 0.53
DNMT3A Q9Y6K1 2/20 0.53
MAPT P10636 3/20 0.51
ABCG2 Q9UNQ0 2/20 0.49
ROCK1 Q13464 1/20 0.46
TGFBR1 P36897 1/20 0.45
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.42
PABPC1 P11940 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL720201 0.87 ROCK2 (0.77) ROCK2RAB9ACYP1A2NPC1CYP3A4
SCHEMBL10036311 0.86 ROCK2 (0.76) ROCK2RAB9ACYP1A2NPC1CYP3A4
SCHEMBL715864 0.86 ROCK2 (0.75) ROCK2RAB9ACYP1A2NPC1CYP3A4
SCHEMBL5308148 0.85 ROCK2 (0.73) ROCK2RAB9ACYP1A2NPC1CYP3A4
SCHEMBL10036308 0.84 ROCK2 (0.76) ROCK2RAB9ACYP1A2NPC1CYP3A4
SCHEMBL5254355 0.84 ROCK2 (1.00) ROCK2RAB9ACYP1A2NPC1CYP3A4
SCHEMBL10036306 0.83 ROCK2 (0.72) ROCK2RAB9ANPC1CYP3A4MAPT
SCHEMBL5254635 0.83 ROCK2 (0.71) ROCK2RAB9ACYP1A2NPC1CYP3A4
SCHEMBL5256438 0.83 ROCK2 (0.71) ROCK2RAB9ACYP1A2NPC1CYP3A4
SCHEMBL5254472 0.83 ROCK2 (0.71) ROCK2RAB9ACYP1A2NPC1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1470121-B1 PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS BAYER HEALTHCARE LLC (US) 2012-07-11 EP claimed
US-20120302587-A1 RHO-KINASE INHIBITORS NAGARAHNAM DHANAPALAN (US) 2012-11-29 US disclosed
US-20120302587-A1 RHO-KINASE INHIBITORS NAGARAHNAM DHANAPALAN (US) 2012-11-29 US disclosed
EP-1470121-B1 PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS BAYER HEALTHCARE LLC (US) 2012-07-11 EP disclosed
US-20120053179-A1 Rho-Kinase Inhibitors NAGARATHNAM DHANAPALAN (US) 2012-03-01 US disclosed
US-20120053179-A1 Rho-Kinase Inhibitors NAGARATHNAM DHANAPALAN (US) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053179-A1 Rho-Kinase Inhibitors CIT, ROCK1, ROCK2 ROCK2 3/4885RAB9A 272/4885CYP1A2 1810/4885
US-20120302587-A1 RHO-KINASE INHIBITORS CIT, ROCK1, ROCK2 ROCK2 3/4885RAB9A 272/4885CYP1A2 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.